| Website | biocartis.com |
| Category | BioTech |
| Phone | +41 21 693 90 51 |
| Employees | |
| Founded | 2007 |
| TOTAL | $137M |
| FUNDING TOTAL | $137M |
| Series B, 4/10 Aescap Venture Debiopharm Group Johnson & Johnson Development Corporation KBC Private Equity Advent Venture Partners | $41.3M |
| Series C, 11/11 Debiopharm Group Johnson & Johnson Development Corporation Wellcome Trust | €71M |
Biocartis SA, a molecular diagnostics company, develops diagnostics technology platform for multiplexed detection of bio-analytes. It focuses on integrated molecular and immunodiagnostics based on its proprietary micro-technology platform. The company develops and licenses a series of technologies to build a diagnostics platform for multiplexed detection, quantification, and amplification of bio-analytes, including proteins, nucleic acids, and small molecules. Its products are used for various applications, including analysis of bio-molecules associated with risks factors, early detection, staging, treatment selection, and monitoring of a disease. Biocartis SA was founded in 2007 and is based in Lausanne, Switzerland.
